Drug Trial Radar · NCT01933932
Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
510
Actual
Start
Sep 25, 2013
Primary completion
Jun 7, 2016
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Sep 2, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the efficacy of selumetinib in combination with docetaxel (75mg/m2) vs placebo in combination with docetaxel (75mg/m2) in patients with locally advance or metastatic NSCLCs that harbor mutations of KRAS. This study will also assess the PK, safety, patient reported outcomes (PRO) and tolerability profile of the selumetinib/docetaxel combination, compared to placebo in combination with docetaxel
Conditions
- Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
Interventions
SelumetinibDrug
Three 25 mg selumetinib capsules (Hyd-Sulfate) be administered orally, twice daily, (total dose 75 mg dose bd) on an uninterrupted schedule.
DocetaxelDrug
Docetaxel 75 mg/m2 will be administered intravenously on day 1 of each 21 day cycle.
PlaceboDrug
Three placebo capsules will be administered orally uninterrupted twice daily in combination with docetaxel 75 mg/m2 intravenously administered on day 1 of each 21 day cycle.
Pegylated G-CSFDrug
All patients will receive pegylated Granulocyte Colony Stimulating Factor (G-CSF) at least 24 hours after administration of every docetaxel dose and not within 14 days prior to the next docetaxel administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS)Time frame: Measured at baseline until the date of first documented objective disease progression. Estimated final completion : approximately 3 years after first subject in (FSI)
Locations
197 sites in 26 countries. Site status is shown where the registry gives one.
Research Site
Aurora, Colorado
Research Site
Pembroke Pines, Florida
Research Site
Atlanta, Georgia
Research Site
Chicago, Illinois
Research Site
Metairie, Louisiana
Research Site
Boston, Massachusetts
Research Site
Boston, Massachusetts
Research Site
Danvers, Massachusetts
Research Site
New York, New York
Research Site
New York, New York
Research Site
Durham, North Carolina
Research Site
Hershey, Pennsylvania
Research Site
Philadelphia, Pennsylvania
Research Site
Nashville, Tennessee
Research Site
Nashville, Tennessee
Research Site
Seattle, Washington
Research Site
Morgantown, West Virginia
Research Site
Buenos Aires, Argentina
Research Site
Ciudad de Buenos Aires, Argentina
Research Site
Ciudad de Buenos Aires, Argentina
Research Site
Córdoba, Argentina
Research Site
Rosario, Argentina
Research Site
Camperdown, Australia
Research Site
Chermside, Australia
Research Site
Darlinghurst, Australia
Research Site
Fitzroy, Australia
Research Site
Kogarah, Australia
Research Site
Kurralta Park, Australia
Research Site
Malvern, Australia
Research Site
Wendouree, Australia
Research Site
Woodville South, Australia
Research Site
Innsbruck, Austria
Research Site
Linz, Austria
Research Site
Salzburg, Austria
Research Site
Vienna, Austria
Research Site
Vienna, Austria
Research Site
Brussels, Belgium
Research Site
Brussels, Belgium
Research Site
Brussels, Belgium
Research Site
Ghent, Belgium
Showing 40 of 197 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.